Table 2 Clinical features associated with differences in lung bacterial community structure (N = 181 subjects).

From: Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort

Lung function and symptom-related outcomes

Bray–Curtis p

Weighted Unifrac p

FVC bronchodilator response (% change)

0.005

0.003

FVC bronchodilator response (mL change)

0.011

0.004

FEV1 bronchodilator response (% change)

0.013

0.032

FEV1 bronchodilator response (mL change)

0.044

0.085

Peak expiratory flow rate, pre-bronchodilator (L/sec)

0.033

0.079

Peak expiratory flow rate, post-bronchodilator (L/sec)

0.036

0.024

FEF25-75, pre-bronchodilator (L/sec)

0.051

0.043

FEF25-75, post-bronchodilator (L/sec)

0.061

0.048

COPD Assessment Test (CAT) score

0.038

0.020

SGRQ total score

0.014

0.017

SGRQ- impact domain

0.009

0.006

SGRQ- activity domain

0.052

0.039

6-min walk distance (meters)

0.003

0.003

6-min walk distance (% predicted)

0.011

0.006

  1. p-values for distance-based PERMANOVA based on 1000 permutations. Variables demonstrating a significant association (p < 0.05) by either distance measure are shown. See also Supplemental Table E3. Lung function and symptom measures are from the annual visit preceding bronchoscopy; 6-min walk distance is from the baseline visit.
Back to article page